Ligand Pharms General CVR (LGNYZ) Net Income by Year
Ligand Pharms General CVR reported $124.5M in net income in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to $51.5M in net income. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Ligand Pharms General CVR has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
LGNYZ Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | TTM | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $51.5M | $124.5Mn/m | -$4.0M-107.7% | $52.2Mn/m | -$33.4M-158.4% | $57.1Mn/m | -$3.0M-100.5% | $629.3M+339.1% | $143.3M+1041.5% | $12.6Mn/m | -$1.6M-100.7% | $229.8M+1811.4% | $12.0M+5.3% | $11.4Mn/m | -$527K-105.4% | $9.7M |
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
LGNYZ Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Ligand Pharms General CVR financials
Frequently Asked Questions
Ligand Pharms General CVR reported $124.5M in net income in fiscal year 2025.
Ligand Pharms General CVR (LGNYZ) reported a $4.0M net loss in fiscal year 2024 and $124.5M in net income in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Ligand Pharms General CVR (LGNYZ) reported $51.5M in net income over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
Across the 15 fiscal years this page covers, Ligand Pharms General CVR (LGNYZ) net income went from $9.7M in fiscal year 2011 to $124.5M in fiscal year 2025.
Ligand Pharms General CVR (LGNYZ) reported -$28.5M in net income in Q3 2026. This represents a decrease of 124.3% from the same quarter a year earlier.
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Ligand Pharms General CVR (LGNYZ) reported on that line in every period on record.